Item 2.02 Results of Operations and Financial Conditions.

On January 7, 2021, Sage Therapeutics, Inc. (the "Company") issued a press release titled "Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference" (the "Press Release"). The Press Release disclosed that, as of December 31, 2020, the Company had a cash balance of $2.1 billion (unaudited). A copy of the Press Release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

The cash figure is unaudited, and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the unaudited cash figure.

The information in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 8.01 Other Events.

The Press Release announced that Barry Greene, the Company's chief executive officer, has agreed to present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, and provided certain corporate updates. A copy of the Press Release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          Press release issued by Sage Therapeutics, Inc. on January 7, 2021.


104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses